Digital Advancements In Clinical Development - What's Next?

By Michelle Longmire, MD, CEO, and Colin Weller, GM Digital Endpoints and Measures

By 2024, significant advancements in digital and artificial intelligence are expected to revolutionize the landscape of clinical development. The use of digital biomarkers in clinical trials is anticipated to increase, enabling real-time, accurate health data collection through wearable devices, mobile apps, and remote monitoring tools. This will allow for more precise measurements of clinical outcomes, reducing the number of trial participants needed.

Decentralized endpoint strategies are also expected to improve trial accessibility for patients in remote or underserved areas. These digital technologies will be used to track a broader range of outcome measures, enhancing treatment efficacy and enabling personalized therapeutic strategies. In addition, the industry has predicted that artificial intelligence and machine learning will be instrumental in advancing digital biomarkers and data analytics, improving endpoint sensitivity and specificity, and reducing the timelines and costs of clinical development.

Discover how this collective of rich datasets will play a crucial role in advancing precision medicine by accessing the article below.